SLS, IBRX, IOVA End October In Red: Merck And AstraZeneca Earnings Put Cancer Bets And Buyout Hopes In Focus
AstraZeneca emphasized ADC combinations, cell therapies and internally developed cancer vaccines as key oncology priorities. Merck highlighted its Moderna-partnered cancer vaccine and new lung-cancer combinations. Sellas’s Phase 3 Regal trial reached 80 deaths, triggering final analysis, with preliminary GPS results expected this quarter. ImmunityBio secured expanded Anktiva approval and expects November trial results that could … Read more